Developing a treatment for multiple sclerosis

Multiple sclerosis (MS) is an autoimmune disease that affects the brain and spinal cord. It affects >100,000 people in the UK and is the commonest neurological cause of disability in adults. Cambridge researchers developed a monoclonal antibody-based drug, Alemtuzumab, which targets the cells responsible for causing damage in MS. The UK is the highest prescribing country worldwide and, as of November 2019, over 25,000 people with MS had been treated with the drug. Alemtuzumab has also had significant commercial impact, generating more than €1.859 billion in net sales.

Added 22 November 2022